2 completed, 1 unknown. 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Completed 2, Unknown 1 |
Follow Lucentis (ranibizumab): new trials by email Literature Review of Lucentis (ranibizumab) trials Research Report on Lucentis (ranibizumab)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Compare Efficacy, Safety, and Immunogenicity of LUBT010 (Proposed Ranibizumab Biosimilar) and Lucentis® in Patients With Neovascular AMD LUBT010 (proposed ranibizumab biosimilar), Lucentis (ranibizumab) - Neovascular Age-related Macular Degeneration | Phase 3 | Completed | Lupin Ltd. | 600 | 2020-09-14 | 2026-01-29 |
| A Study to Compare SB11 (Proposed Ranibizumab Biosimilar) to Lucentis in Subjects With Neovascular Age-related Macular Degeneration (AMD) SB11 (Proposed ranibizumab biosimilar), Lucentis (ranibizumab) - Age-Related Macular Degeneration | Phase 3 | Completed | Samsung Bioepis Co., Ltd. | 705 | 2018-03-14 | 2021-05-21 |
| Evaluation of Ranibizumab in Proliferative Diabetic Retinopathy (PDR) Requiring Vitrectomy Lucentis (ranibizumab) - Proliferative Diabetic Retinopathy | Phase 3 | Unknown | Retina Associates, Kansas City | 40 | 2007-08-01 | 2007-08-15 |
Lupin Ltd. (1) · Retina Associates, Kansas City (1) · Samsung Bioepis Co., Ltd. (1)
United States (3) · Hungary (2) · India (2) · Poland (2) · Russia (2) · Bulgaria (1) · Czechia (1) · Germany (1) · Slovakia (1) · South Korea (1) · United Kingdom (1)
Gregory M Fox, MD (1) · Se Joon Woo (1)
PMID 33211076, PMID 36520462, PMID 37260074
2017 (1)